Sanofi

News

Could OTC Cialis for erectile dysfunction reach the US?

Sanofi's consumer healthcare unit Opella could finally be able to bring an OTC PDE-5 inhibitor for erectile dysfunction to the US market.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Sanofi takes SK Bio-partnered pneumococcal shot into phase 3

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.

News

Adult holding the hand of a newborn baby

MSD eyes June verdict for paediatric RSV antibody

The FDA has started a review of MSD's RSV antibody clesrovimab, a potential rival to Beyfortus, with a verdict due in the middle of next year.

News

Teva, Sanofi score well with anti-TL1A drug in IBD test

Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.

News

Sanofi opens $595m manufacturing facility in Singapore

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products

Could OTC Cialis for erectile dysfunction reach the US?

11 blockbuster drugs to look out for in 2025

Sanofi takes SK Bio-partnered pneumococcal shot into phase 3

MSD eyes June verdict for paediatric RSV antibody

Teva, Sanofi score well with anti-TL1A drug in IBD test

Sanofi opens $595m manufacturing facility in Singapore

Bayer gets swift review for Kerendia in type 1 diabetes

Discover a new era of healthcare panel engagement: Grounded ...

Sanofi

Editor's Picks